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Abstract 
Introduction: Approximately 25–30% of breast cancers are assumed to be HER-2/neu 
positive. It is well known that HER-2/neu-positive cancers after treatment with 
trastuzumab can become HER-2/neu negative. Change in HER-2/neu status from negative 
to positive following treatment has not been well studied. We describe a patient with 
inflammatory breast cancer who was initially HER-2/neu negative but became positive 
after treatment. A 59-year-old postmenopausal white female saw her surgeon for 
violaceous discoloration of the left breast for 4 months. The surgeon palpated a mass 
measuring 6 cm in the patient’s left breast. Additionally, there was violaceous 
discoloration involving two thirds of the breast. Biopsy of the breast mass and skin 
revealed inflammatory breast cancer. The tumor was estrogen receptor positive, 
progesterone receptor positive and HER-2/neu negative. The patient was given four 
cycles of chemotherapy with cyclophosphamide, doxorubicin and docetaxol. She 
subsequently underwent a mastectomy, excision of the skin over the chest wall and 
axillary node dissection. Of the axillary lymph nodes, 14/14 were involved. The tumor 
was still estrogen receptor positive and progesterone receptor positive, but HER-2/neu 
was 2+ by immunohistochemistry and amplified at 3.3 as detected by fluorescent in situ 
hybridization. The patient received trastuzumab along with chemotherapy followed by 
radiation therapy and letrozole. She is currently receiving trastuzumab and letrozole in 
the adjuvant setting and appears to be doing well.  
Conclusion: A breast cancer which was initially HER-2/neu negative can become positive 
following treatment. Therefore, re-biopsy may be necessary during the course of 
treatment of breast cancer to re-assess the HER-2/neu status. This gives the clinician the  
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opportunity to include drugs like trastuzumab and lapatinib in the treatment of patients 
with a transformation to HER-2/neu-positive cancer. 
 
Introduction 
It has been reported that approximately 25–30% of breast cancers are HER-2/neu 
positive [1, 2]. It has previously been documented that HER-2/neu-positive cancers may 
become negative following treatment with trastuzumab [3]. However, transformation of 
cancer status from HER-2/neu negative to positive has not been widely studied. 
Therefore, re-assessment of HER-2/neu status in patients undergoing treatment of HER-
2/neu negative breast cancer is uncommon. In this case report, we describe a patient 
whose breast cancer changed from HER-2/neu negative to positive following treatment 
with chemotherapy and discuss the implications of this change on the clinical 
management of breast cancer. 
Case Presentation 
A 59-year-old postmenopausal white female noticed violaceous discoloration of her left breast for 
nearly 4 months prior to visiting her gynecologist. The gynecologist referred the patient to a surgeon 
who palpated a 6-cm mass in the left breast and noted significant edema of the skin as well as peau 
d’orange appearance in the left breast. Additionally, there was left supraclavicular and left axillary 
lymphadenopathy. A Monopty biopsy of the left breast mass as well as a skin biopsy was done. CT scan 
of the chest, abdomen and pelvis revealed extensive bilateral axillary adenopathy, anterior chest wall 
lymphadenopathy, soft tissue edema, and inflammation of the anterior and left chest wall. The 
pathology of the left breast mass and skin biopsy was consistent with inflammatory breast cancer (fig. 1, 
fig. 2). Her tumor was estrogen receptor positive, progesterone receptor positive and HER-2/neu 
negative by immunohistochemistry (1+) (fig. 3, fig. 4) and unamplified at 1.1 as detected by fluorescent 
in situ hybridization (FISH). The patient was treated with four cycles of chemotherapy with 
cyclophosphamide (500 mg/m
2), doxorubicin (50 mg/m
2), and docetaxol (75 mg/m
2). The patient 
received 6 mg s.c. pegfilgrastim the day after chemotherapy with each cycle. Although the mass 
decreased in size, the discoloration of the breast continued to worsen. The patient subsequently had a 
mastectomy, which revealed inflammatory breast cancer with 14/14 axillary lymph nodes positive for 
metastatic carcinoma. The patient’s breast tumor was estrogen receptor positive, progesterone receptor 
positive and HER-2/neu positive (2+) and amplified at 3.3 as detected by FISH. The patient received 
trastuzumab (4 mg/kg i.v.) along with chemotherapy with paclitaxel (150 mg/m
2) and gemcitabine 
(2,000 mg/m
2) every 2 weeks. Radiation therapy was administered to the left chest wall and nodal areas 
(50 Gy) as well as to the mastectomy scar (60 Gy). The patient completed her postoperative 
chemoradiotherapy and is currently on trastuzumab and letrozole 2.5 mg p.o. daily.  
Discussion 
This case indicates the possibility that an initially HER-2/neu-negative breast cancer 
can become HER-2/neu positive following treatment with chemotherapy. Breast cancer is 
well known to be heterogeneous and it is possible that the initial biopsy may have been 
negative due to sampling error and that only the mastectomy specimen revealed the true 
HER-2/neu status of the neoplasm (fig. 5, fig. 6). Another possible explanation is that the 
chemotherapy preferentially reduced the burden of the HER-2/neu-negative component 
in the breast cancer while permitting growth of the HER-2/neu-positive component.   
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Regardless of the mechanism of this transformation, a change in cancer status from 
HER-2/neu negative to positive has important clinical implications. Had this change in 
HER-2/neu status not been identified following the mastectomy, this patient would not 
have been offered trastuzumab treatment, which markedly improves survival of patients 
with HER-2/neu-positive breast cancers [4]. Recent research has demonstrated that 
conversion from HER-2/neu negative to positive can occur in up to 3.5% of the cases [5]. 
However, this has not often been reported. As a result, patients with HER-2/neu-negative 
breast cancers are not commonly re-biopsied to assess change in status. This case 
demonstrates that in patients with worsening condition despite chemotherapy, re-
assessment of the HER-2/neu status may be justified.  
Conclusion 
In this report we have shown that HER-2/neu-negative breast cancers can become 
positive following treatment. In patients with breast cancer (even metastatic) who are not 
responding to treatment, it may be reasonable to re-biopsy to assess their HER-2/neu 
status. Although transformation of HER-2/neu status from negative to positive may be 
uncommon, the changed status may open up new avenues of treatment like trastuzumab 
or lapatanib. These treatments would not be offered without re-assessment of the HER-
2/neu status. 
 
 
 
 
 
 
Fig. 1. This is a low-power view of the skin from the core biopsy showing clusters of breast carcinoma 
cells. Hematoxylin and Eosin. 
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Fig. 2. This is a high-power view of the breast carcinoma cells within the dermal blood vessels. 
Hematoxylin and Eosin. 
 
 
 
Fig. 3. This is a low-power image of the positive control slide for HER-2/neu. Cells staining gold 
amplify HER-2/neu. HER-2/neu immunohistochemistry stain. 
 
 
 
Fig. 4. This is a high-power image of the breast carcinoma cells in the skin showing a negative reaction 
for HER-2/neu. HER-2/neu immunohistochemistry stain. 
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Fig. 5. This is a low-power view of the breast carcinoma cells in the skin showing a positive reaction for 
HER-2/neu. HER-2/neu immunohistochemistry stain. 
 
 
 
Fig. 6. Following mastectomy, HER-2/neu is positively amplified at 3.3. FISH. 
 
 
 
 
 
 
 
 
 
 
 
  
Case Rep Oncol 2011;4:19–24 
DOI: 10.1159/000324114 
Published online: 
January 18, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
24
References 
1  Chang HR: Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 
2010;116:2856–2867. 
2  Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of 
relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–182. 
3  Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, 
Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM: Loss of HER2 amplification following 
trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009;15:7381–7388. 
4  Romond EH, Perez EA, Bryant J, Suman V, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman 
PE, Swain SM, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, 
Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J 
Med 2005;353:1673–1684. 
5  Hirata T, Shimizu C, Yonemori K, Hirakawa A, Kouno T, Tamura K, Ando M, Katsumata N, Fujiwara Y: 
Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact 
on the long-term outcome in patients with primary breast cancer. Br J Cancer 2009;101:1529–1536. 